Oncolytics Biotech is trading 5.98% higher at $0.52, with no clear reason established for the intraday gain. - On October 14, the company updated its GOBLET study, with final Cohort 4 results expected in Q4 2026 and initial Cohort 5 results in the first half of 2027. - It expects a final PanCAN grant payment later this quarter. - Broader markets were under pressure after hotter-than-forecast annual headline and core CPI readings, while biotech was also lower. Neither trend directly explains the gain.